Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 5.74 is 12% below its 5-year average of 6.55, near the low end of its 5-year range (0.90–20.75).
As of the fiscal period ended Tuesday, June 30, 2026. 93.51% above its 12-month average of 2.97.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 5.74.
QUICK RATIO (ACID-TEST)
5.74
QUICK RATIO (ACID-TEST) AVG TTM
2.97
QUICK RATIO (ACID-TEST) AVG 3Y
4.41
QUICK RATIO (ACID-TEST) AVG 5Y
6.55
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+93.51%
CURRENT VS 3Y AVG
+30.25%
CURRENT VS 5Y AVG
-12.32%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
2.99
median of 509 covered companies
CURRENT VS SECTOR MEDIAN
+91.97%
vs the sector median at left
Humacyte, Inc.
Market Cap
$84.17M
Quick Ratio (Acid-Test)
5.74
TTM Avg
2.97
3Y Avg
4.41
5Y Avg
6.55
Market Cap
$84.13M
Quick Ratio (Acid-Test)
7.03
TTM Avg
3.05
3Y Avg
3.90
5Y Avg
4.20
Market Cap
$84.79M
Quick Ratio (Acid-Test)
1.98
TTM Avg
0.61
3Y Avg
1.40
5Y Avg
2.59
Market Cap
$85.60M
Quick Ratio (Acid-Test)
7.99
TTM Avg
9.12
3Y Avg
12.06
5Y Avg
14.25
Market Cap
$87.96M
Quick Ratio (Acid-Test)
1.01
TTM Avg
1.14
3Y Avg
1.20
5Y Avg
1.25
Market Cap
$88.21M
Quick Ratio (Acid-Test)
2.71
TTM Avg
1.86
3Y Avg
1.80
5Y Avg
2.82
Market Cap
$79.78M
Quick Ratio (Acid-Test)
0.34
TTM Avg
0.10
3Y Avg
0.26
5Y Avg
0.26
Market Cap
$78.83M
Quick Ratio (Acid-Test)
1.00
TTM Avg
2.08
3Y Avg
2.75
5Y Avg
4.86
Market Cap
$88.63M
Quick Ratio (Acid-Test)
3.30
TTM Avg
5.38
3Y Avg
8.10
5Y Avg
12.75
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Humacyte, Inc. (HUMA) | $84.17M | 5.74 | 2.97 | 4.41 | 6.55 |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | 7.03 | 3.05 | 3.90 | 4.20 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.79M | 1.98 | 0.61 | 1.40 | 2.59 |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $85.60M | 7.99 | 9.12 | 12.06 | 14.25 |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 1.01 | 1.14 | 1.20 | 1.25 |
| ImmuCell Corporation (ICCC)vs › | $88.21M | 2.71 | 1.86 | 1.80 | 2.82 |
| Citius Oncology, Inc. (CTOR)vs › | $79.78M | 0.34 | 0.10 | 0.26 | 0.26 |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.83M | 1.00 | 2.08 | 2.75 | 4.86 |
| Cardiff Oncology, Inc. (CRDF)vs › | $88.63M | 3.30 | 5.38 | 8.10 | 12.75 |
| Conexeu Sciences Inc. (CNXU)vs › | $88.97M | N/A | N/A | N/A | N/A |
Quick Ratio
5.74
Excludes inventory
Current Ratio
6.21
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 5.74 |
| 2026-03-31 | 3.32 |
| 2025-12-31 | 2.95 |
| 2025-09-30 | 0.90 |
| 2025-06-30 | 1.93 |
| 2025-03-31 | 3.28 |
| 2024-12-31 | 2.40 |
| 2024-09-30 | 1.10 |
| 2024-06-30 | 5.41 |
| 2024-03-31 | 8.37 |
| 2023-12-31 | 4.52 |
| 2023-09-30 | 6.79 |
| 2023-06-30 | 10.59 |
| 2023-03-31 | 5.67 |
| 2022-12-31 | 7.88 |
| 2022-09-30 | 9.75 |
| 2022-06-30 | 17.46 |
| 2022-03-31 | 19.45 |
| 2021-12-31 | 20.75 |
| 2021-09-30 | 11.49 |
| 2021-06-30 | 1.95 |
| 2021-03-31 | 3.03 |
| 2020-12-31 | 3.69 |
| 2020-09-30 | 11.18 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 8.76 |
